Analysis for CHIP mutations in the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS) clinical trial cohort (ClinicalTrials.gov NCT01327846), in which canakinumab (anti–IL-1β antibody) was administered to patients with prior myocardial infarction, revealed decreased subsequent major adverse cardiovascular events (MACEs) in subjects with TET2 mutations relative to those without CHIP (91). This evidence concerns the gene STUB1 and deep vein thrombosis.